Clinical significance of day-night differences in serum theophylline concentration with special reference to Theo-Dur
- PMID: 3771961
- DOI: 10.1016/0091-6749(86)90051-5
Clinical significance of day-night differences in serum theophylline concentration with special reference to Theo-Dur
Abstract
In two studies, 25 diurnally active patients with asthma (6 to 17 years of age) were evaluated at steady state for day-night differences in serum theophylline concentration (STC) by frequent blood sampling over two consecutive 12-hour dosing intervals while being given treatment with Theo-Dur. In both studies findings were similar; Cmax was greater and Tmax shorter after dosing at 7 A.M. or 8 A.M. versus 7 P.M. or 8 P.M., with Cmax-C min approximately 7 micrograms/ml. For the morning dosing, 22 of 25 patients exhibited Cmax within 4 hours; 23 of 25 exhibited C min 12 hours after dosing. For the evening ingestion, the situation was very different: C min occurred within the initial 4 hours in 22 of 25 patients, whereas Cmax occurred in 22 of 25 patients just before the next (morning) dose. The findings indicate that the most appropriate time to estimate Cmax in patients given Theo-Dur is within the 4 hours after morning ingestion. The best time to estimate C min is a few hours after the evening ingestion. Sampling at these times is likely to represent within 10% to 20% the actual Cmax or C min.
Similar articles
-
Clinical relevance of theophylline chronokinetics for asthmatic children.Prog Clin Biol Res. 1987;227B:259-70. Prog Clin Biol Res. 1987. PMID: 3628336
-
Theophylline absorption from two sustained-release products. Implications for therapeutic drug monitoring.Am Rev Respir Dis. 1987 Nov;136(5):1168-73. doi: 10.1164/ajrccm/136.5.1168. Am Rev Respir Dis. 1987. PMID: 3674579
-
Theophylline absorption from sustained-release products: comparative steady-state bioavailability of once-daily Theo-Dur, Theo-24, and Uniphyl.J Clin Pharmacol. 1987 Nov;27(11):855-61. doi: 10.1002/j.1552-4604.1987.tb05579.x. J Clin Pharmacol. 1987. PMID: 3429692
-
A clinical and pharmacokinetic basis for the selection and use of slow release theophylline products.Clin Pharmacokinet. 1984 Mar-Apr;9(2):95-135. doi: 10.2165/00003088-198409020-00001. Clin Pharmacokinet. 1984. PMID: 6370542 Review.
-
Update on the pharmacodynamics and pharmacokinetics of theophylline.Chest. 1985 Aug;88(2 Suppl):103S-111S. doi: 10.1378/chest.88.2_supplement.103s. Chest. 1985. PMID: 3893922 Review.
Cited by
-
Therapeutic drug monitoring in the neonate and paediatric age group. Problems and clinical pharmacokinetic implications.Clin Pharmacokinet. 1990 Jul;19(1):1-10. doi: 10.2165/00003088-199019010-00001. Clin Pharmacokinet. 1990. PMID: 2199125 Review.
-
Rate and extent of drug accumulation after multiple dosing revisited.Clin Pharmacokinet. 2010 Jul;49(7):421-38. doi: 10.2165/11531190-000000000-00000. Clin Pharmacokinet. 2010. PMID: 20528003 Review.
-
Toxic interaction between fluvoxamine and sustained release theophylline in an 11-year-old boy.Drug Saf. 1991 Nov-Dec;6(6):460-2. doi: 10.2165/00002018-199106060-00006. Drug Saf. 1991. PMID: 1793525
-
Novel drug delivery systems. An overview of their impact on clinical pharmacokinetic studies.Clin Pharmacokinet. 1991 Jan;20(1):1-14. doi: 10.2165/00003088-199120010-00001. Clin Pharmacokinet. 1991. PMID: 2029799 Review. No abstract available.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources